Most Popular Angioplasty Web Site
Stent Center Stent Center
with support from Medtronic Cardiovascular
Medtronic's IN.PACT Drug-Coated Balloon Shows Safety and Efficacy for Peripheral Angioplasty in Diabetics
Sub-study Presented at VIVA 14 Shows Similar Improvements in Primary Patency and TLR for both Diabetics and Non-Diabetics
Share This Story:
Bookmark and Share

external sites:
Medtronic, Inc.

IN.PACT Admiral Drug-Coated Balloon
IN.PACT Admiral Drug-Coated Balloon
November 4, 2014 -- Data presented this morning at the VIVA 14 meeting in Las Vegas, Nevada, showed that patients treated with Medtronic's IN.PACT Admiral drug-coated balloon (DCB) for narrowings in their legs above-the-knee had significantly better outcomes than those treated with the standard "plain" balloon catheter, called percutaneous transluminal angioplasty (PTA).

While these data were previously presented in April at the Charing Cross international symposium in London, today's session also showed that these positive findings for the DCB held true even for patients with diabetes, a population that typically presents with worse arterial disease and has poorer outcomes compared to non-diabetics.

Two Outcome Measures - Both Favored Drug-Coated Balloon
Assessing the success of the peripheral angioplasty procedure can be looked at in two ways: primary patency, which is defined as restoration of adequate blood flow through the treated arterial segment, and clinically-driven target lesion revascularization, a repeat procedure that is performed because of recurrent symptoms related to the treated blockage. The overall outcomes at one-year for the DCB vs PTA in primary patency were 82.2% vs 52.4%, with a highly significant p value of P < .001). These values were slightly higher when adjusted via Kaplan-Meier survival estimates. For the pre-defined diabetic cohort, the primary patency rates were 77.3% vs 49.0%; P = .005.

The differences in clinically-driven target lesion revascularization were even more dramatic: 2.4% vs. 20.6%; P < .001. For the diabetic patients, the outcomes were 3.7% vs 23.1%; P < .001.

The IN.PACT DCB has been approved in Europe and other countries for over five years. Medtronic is hoping to gain FDA approval for use in the U.S. sometime next year. The FDA approved C.R. Bard's Lutonix DCB last month; it currently is the only DCB approved for sale in the U.S.

This morning's press release from Medtronic, Inc. follows:

Medtronic Drug-Coated Balloon for Peripheral Artery Disease Also Benefits Patients with Diabetes in Landmark Study
Consistent Outcomes Despite Common and Challenging Comorbidity Reinforce Overall Findings of IN.PACT SFA Trial

November 4, 2014 -- Las Vegas, Nevada -- For the treatment of peripheral artery disease in leg arteries above the knee, the IN.PACT Admiral drug-coated balloon from Medtronic, Inc. (NYSE: MDT) provided a consistently favorable treatment effect in patients with diabetes in a landmark study of the investigational medical device, which is under review by the U.S. Food and Drug Administration (FDA) for approval.

Dr. Peter Schneider
Dr. Peter Schneider

This finding comes from a pre-specified subgroup analysis of patients with diabetes in the IN.PACT SFA Trial that was presented today at the Vascular InterVentional Advances 2014 (VIVA 14) meeting during a late-breaking clinical trials session by Dr. Peter Schneider, chief of vascular surgery at Kaiser Foundation Hospital in Honolulu.

"Peripheral artery disease in patients with diabetes tends to be more advanced and complex and, as a result, more challenging to treat than it is in patients without diabetes," explained Dr. Schneider, a principal investigator of the IN.PACT SFA Trial. "While that tendency held true in this study, diabetes did not negate the magnitude of the difference in treatment effect. The patency rates were statistically significantly higher, by more than 20 percent, for all patients in the drug-coated balloon arm and for its diabetic patient subset."

IN.PACT SFA Trial - 12-Month Outcomes
Diabetes Subgroup Analysis
Primary Patency at 360 Days * DCB PTA p-value
All Patients ((n=220 DCB, n=111 PTA) 89.8% 66.8% p<0.001
Diabetic Patients (n=89 DCB, n=54 PTA) 82.7% 62.3% p=0.015
* Kaplan-Meier survival estimates

The IN.PACT SFA trial enrolled 331 subjects at 57 sites across Europe and the United States. All study subjects were randomized to treatment with the drug-coated balloon (DCB) or percutaneous transluminal angioplasty (PTA).

Key outcomes from all patients in the IN.PACT SFA Trial were presented for the first time in April 2014 at the Charing Cross International Symposium in London and will soon be published in a peer-reviewed medical journal:

  • The clinically driven target lesion revascularization (CD-TLR) rates at 12 months were 2.4 percent for the DCB group and 20.6 percent for the PTA group (p<0.001), a highly statistically significant difference. CD-TLR accounts for repeat procedures due to recurrent symptoms related to the treated lesion.
  • Per protocol, primary patency rates were assessed at 12 months of follow-up and showed a highly statistically significant difference: 82.2 percent for the DCB group and 52.4 percent for the PTA group (p<0.001). Primary patency at 360 days was also calculated by Kaplan-Meier survival estimates; at this specific time point, it was 89.8 percent for the DCB group and 66.8 percent for the PTA group. Primary patency means a restoration of adequate blood flow through the treated segment of the diseased artery.

Study subjects were well matched at the time of enrollment. The vast majority (approximately 95 percent) of the patients had moderate or severe claudication, a condition characterized by leg pain while walking due to restricted blood flow through the superficial femoral artery (SFA) or proximal popliteal artery (PPA). The remaining five percent suffered from rest pain because of more advanced arterial disease.

In addition to disease severity, other baseline characteristics -- including diabetes (40.5% vs. 48.6%) and hypertension (91.4% vs. 88.3%), as well as mean lesion length (8.94 cm vs. 8.81 cm) and percent of total occlusions treated (25.8% vs. 19.5%) -- were similar between the two groups, with no statistically significant differences. Clinical outcomes, however, significantly favored the DCB group.

The IN.PACT Admiral drug-coated balloon received the CE (Conformité Européene) mark in 2009 and has been used in standard clinical practice in Europe since then. It remains an investigational medical device in the United States, pending FDA approval.

Approximately 650,000 to 700,000 people in the United States and Western Europe undergo an interventional procedure each year for this common form of peripheral artery disease, which typically involves the superficial femoral artery (SFA). In collaboration with leading clinicians, researchers and scientists, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular diseases and cardiac arrhythmias. The company strives to offer products and services that deliver clinical and economic value to healthcare consumers and providers worldwide.

About Medtronic
Medtronic, Inc. (, headquartered in Minneapolis, is the global leader in medical technology -- alleviating pain, restoring health and extending life for millions of people around the world.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Reported by Burt Cohen, November 4, 2014